Participant knowledge regarding breast cancer
REGRESSION, DISEASE, DISEASE CHARACTERISTIC
Participants' knowledge about their diagnosis and guideline‐recommended therapy was evaluated twice. A total of 141 patients completed the survey at the first prespecified timepoint after a median of 18 days (95% CI 15–19) since randomization and receipt of their corresponding brochure. One hundred forty‐nine participants completed the survey at the second‐prespecified timepoint after a median of 45 days (95% CI 42–48.7) from intervention allocation. At the first knowledge assessment available for each participant (median of 19 days [95% CI 18–20] post‐randomization), 75 of 157 respondents (48%) correctly identified their disease stage, 85 of 165 patients (52%) identified their molecular subtype, and 44 of 148 respondents (30%) accurately identified the systemic therapies they were eligible for according to their individual disease characteristics.A total of 125 (76%) participants answered the knowledge survey at both prespecified follow‐up periods. Overall, the proportion of patients that correctly identified their clinical stage improved upon second assessment (45% vs. 76%, Proportion of patients that correctly identified their clinical stage, molecular subtype, and systemic treatment options according to their disease characteristics on the first (left) and second (right) assessment. The colored lines between assessments represent the change in response between assessments, weighted according to the proportion of participants. Represented in green are participants that answered accurately, in yellow those that responded “I don't know,” and in red those that answered inaccurately in the second assessment.Table Participants' knowledge about their diagnosis and treatment options according to their disease characteristics at first and second assessment.
Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor.Bold values are statistically significant Univariate logistic regression analyses were performed to assess factors associated with identification of clinical stage, molecular subtype, and systemic therapy options per individual disease characteristics in the first knowledge survey available (Table Univariate logistic regression analyses.Abbreviation: OR, odds ratio.Bold values are statistically significant 